EPHA3

Overview

One-paragraph summary of the gene’s role and why it matters in cancer genomics.

Alterations observed in the corpus

  • Mutation classes (missense / truncating / fusion / amplification / deletion) with links to the papers that report them.
  • 11 mutations in 188 LUAD tumours; first statistically significant demonstration in LUAD; K761N mutation in kinase domain at conserved ‘molecular brake’ position. PMID:18948947
  • Identified as a significantly mutated gene in a prior nearly all-Caucasian MSS CRC cohort; cited as evidence that different EPH family members are selected in different ethnic backgrounds PMID:25583493
  • EPHA3 mutations occur in 3 ATC (anaplastic thyroid cancer) cases as ATC-only low-frequency hits in the MSK-IMPACT 341-gene panel cohort (n=117 advanced thyroid tumors); EPHA3 is classified as an RTK hit in the residual ATC landscape beyond the dominant BRAF/RAS/TP53 drivers PMID:26878173

Cancer types (linked)

  • Per cancer type: prevalence, co-mutation patterns, clinical significance.

Co-occurrence and mutual exclusivity

  • Linked partner genes with the relationship and the paper(s) reporting it.

Therapeutic relevance

  • Drugs (linked) targeting this gene or its pathway, with the studies supporting them.

Open questions

  • Conflicts or unresolved findings across papers.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:18948947

This page was processed by crosslinker on 2026-05-14. - PMID:25583493

This page was processed by crosslinker on 2026-05-14. - PMID:26878173

This page was processed by wiki-cli on 2026-05-14.